Pseudoxanthoma elasticum resulting in acute coronary syndrome

Hiroki Ono; Akira Oshita; Shinji Inaba; Moeko Kawamata; Yasuhisa Nakao; Teruyoshi Uetani; Jun Muto; Takeshi Joko; Hideo Kawakami

doi:10.1016/j.jccase.2022.06.004

Pseudoxanthoma elasticum resulting in acute coronary syndrome

J Cardiol Cases. 2022 Aug 16;26(4):308-310. doi: 10.1016/j.jccase.2022.06.004. eCollection 2022 Oct.

Authors

Hiroki Ono¹, Akira Oshita¹, Shinji Inaba², Moeko Kawamata¹, Yasuhisa Nakao², Teruyoshi Uetani¹, Jun Muto³, Takeshi Joko⁴, Hideo Kawakami¹

Affiliations

¹ Department of Cardiology, Ehime Prefectural Imabari Hospital, Imabari, Ehime, Japan.
² Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
³ Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
⁴ Department of Ophthalmology, Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan.

Abstract

Pseudoxanthoma elasticum (PXE) is a rare hereditary disorder that causes elastic tissue degeneration in the skin, eyes, and cardiovascular system. Gastrointestinal bleeding and fundus hemorrhage are serious complications associated with PXE prognosis as well as cardiovascular involvement. This is a rare case of acute coronary syndrome in a PXE patient with high bleeding risk.

Learning objective: Pseudoxanthoma elasticum (PXE) resulting in acute coronary syndrome (ACS) is rare. Given PXE patients are generally at very high bleeding risk, antithrombotic therapy as secondary prevention after ACS onset should be taken into full consideration.

Keywords: Acute coronary syndrome; Antithrombotic therapy; Pseudoxanthoma elasticum.

Publication types

Case Reports